INFORMATION ON PROPOSED NEW BOARD MEMBERS

David Jern

<u>Born</u>: 1973

<u>Education and experience</u>: Master's degree in biomedical engineering and 2 years of economics studies. Previously worked as a management consultant in the healthcare sector in Switzerland and Sweden and as CEO in several medium-sized companies in the healthcare sector.

<u>Other current roles</u>: CEO of Alumbra Group AB, board member of MedCap AB (publ) and chairman of Bioswed Scientific AB.

<u>Independence</u>: Independent in relation to the company and its management as well as in relation to major shareholders.

Holdings: Does not own, directly or indirectly, shares or share-related instruments in OssDsign.

Tomas Blomquist

<u>Born</u>: 1970

<u>Education and experience</u>: Tomas Blomquist has more than 30 years of international experience in the healthcare sector, with a particular focus on Life Science Tools, Diagnostics, and Medtech. He has held executive positions at global companies such as Abbott, Roche, Johnson & Johnson, and Analyticon Biotechnologies. Tomas served as CEO and President of Biotage AB from 2019 until January 2024. He has also been a member of management teams and boards in several international companies. Tomas possesses extensive expertise in corporate strategy, vision and culture, team and leadership development, business model innovation, M&A, internationalization, organizational design, and commercialization. He holds an education from the Stockholm School of Economics, where he completed the Advanced Management Program as well as the Executive Management Program.

Other assignments: Tomas is a board member of Nolato AB (since May 2021).

<u>Independence</u>: Independent in relation to the company and its management as well as in relation to major shareholders.

Holdings: Does not own, directly or indirectly, shares or share-related instruments in OssDsign.